Fredag 9 Maj | 13:20:53 Europe / Stockholm
Svenska | English

Gubra

Bifogade filer

Prenumeration

Kalender

Est. tid*
2026-02-27 N/A Bokslutskommuniké 2025
2025-08-21 07:30 Kvartalsrapport 2025-Q2
2025-04-04 - X-dag ordinarie utdelning GUBRA 0.00 DKK
2025-04-03 - Årsstämma
2025-02-28 - Bokslutskommuniké 2024
2024-08-23 - Kvartalsrapport 2024-Q2
2024-04-04 - X-dag ordinarie utdelning GUBRA 0.00 DKK
2024-04-03 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-01 - Extra Bolagsstämma 2023
2023-08-25 - Kvartalsrapport 2023-Q2

Beskrivning

LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Gubra är ett läkemedelsbolag. Bolagets verksamhet är fokuserad på de tidiga stadierna av läkemedelsutveckling. De driver huvudsakligen forskning och utveckling inom området för metabola och fibrotiska sjukdomar.. Bolagets produktportfölj innefattar ett flertal varumärken och läkemedel, och verksamheten bedrivs på global nivå, med störst närvaro inom Nordamerika och Norden. Huvudkontoret ligger i Hørsholm, Danmark.
Major shareholder announcement
2023-04-06 16:33:00

Gubra A/S, CVR no. 30514041 (the “Company” or “Gubra”) hereby announces that it has received a major shareholders' announcement pursuant to section 38 of the Danish Capital Markets Act regarding Danske Bank A/S ("Danske Bank").
 
Danske Bank has informed the Company that it, through its 100% owned subsidiaries as detailed in the attached, including Danica Pension, Livsforsikringsaktieselskab (“Danica”) and Danske Invest Management A/S (“Danske Invest”), in aggregate holds a total of 1,042,474 shares in the Company, each with a nominal value of DKK 1. In total, Danske Bank owns a total of 1,042,474 shares with a nominal value of DKK 1 each, corresponding to 6.38% of the total share capital and voting rights of the Company.
 
The Company understands that a number of shares held by Danske Invest are excluded from the calculation of shares held by Danske Bank as set out above.

Contacts
Media: Sofia Pitt Boserup, sbo@gubra.dk, +45 4188 9586
Investors: Kristian Borbos, kbo@gubra.dk, +45 3080 8035

About Us
Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information.

This information is information which Gubra is obliged to make public pursuant to the Danish Capital Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-04-06 16:33 CEST.

Attachments
Major shareholder announcement
Gubra Notification Of Danske Bank Major Holding

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden